Nebula Research & Development LLC Phathom Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $852 Billion
- Q4 2024
A detailed history of Nebula Research & Development LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 20,963 shares of PHAT stock, worth $138,355. This represents 0.02% of its overall portfolio holdings.
Number of Shares
20,963Holding current value
$138,355% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
157Shares Held
68.4MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$66.7 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$49.3 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$46.6 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$24.2 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$23.1 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $259M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...